Criteria 1. Unparterned 2. Not enough cash to bring the product to market 3. Lets say at least started Phase 3 trials 4. Its on a product basis so if company a has 2 unparterned Phase 3 products and not enough cash then an entry for each would be appropriate
Stock Product Stage Comments ----- --------------- --------------------- ----------------------------- NTII Viprinex Phase 3 Interim analysis January '09. Stroke Drug, high chance of failure. BPAX Libigel Phase 3 ~2010 Submit Adequate Safety? EPIX Vasovist PDUFA 12/30/08 FDA initially rejected saying 2 more studies needed. Allowed reread company states results very positive. Looking to sell outright on approval. RPRX Proellex Phase 3 Uterine fibroids CHTP Droxidopa Pivotal Phase III Orthostatic hypotension. Results expected 02/09 JAV Dyloject Phase III Approved in UK. Post operative Pain (injectable) JAV Dyloject Phase III Acute moderate-to-severe pain (intranasal)
----- 1. Reply to this post copying all the text 2. Please put [ pre ] at the begining of the table without surrounding spaces. 3. Please put [ /pre ] at the end of the table without surrounding spaces.